MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack, delivering therapeutics on a programmed schedule to promote healing and regeneration. In rat studies, the patch reduced damaged tissue by 50% and significantly improved cardiac function, offering a potential breakthrough for post-myocardial infarction treatment.
The European Union has initiated funding for the European Research Institute on Simulation (ERIS), a coordinated effort to address the fragmentation of simulation-based medical education across member states. The two-year project, running from 1 May 2025 to 30 April 2027, aims to establish the first pan-European framework for simulation training in interventional cardiac electrophysiology.
GE HealthCare has secured FDA 510(k) clearance for its Revolution Vibe CT system, a cardiac imaging platform designed to capture full-heart clarity in a single beat without requiring electrocardiogram trace. The system addresses growing demand for coronary CT angiography (CCTA) as cardiovascular disease continues to account for projected annual deaths exceeding 23 million globally by […]
Comprehensive cardiac monitoring reveals that low aerobic fitness and advancing age independently drive irregular heartbeat patterns previously dismissed as benign, with implications for preventive screening strategies starting at age 50.
A major international clinical trial has overturned four decades of standard cardiac care, finding that beta-blockers provide no benefit for most heart attack survivors with preserved heart function. The REBOOT study, involving over 8,500 patients, could reshape treatment guidelines worldwide.
Researchers at the National University of Singapore have developed a revolutionary biomaterial that demonstrates how environmental changes around heart cells could reverse age-related cardiac damage. The breakthrough research suggests that targeting the cellular environment, rather than the cells themselves, may offer new therapeutic pathways for heart rejuvenation.
A groundbreaking contactless detection system for atrial fibrillation using radio technology and artificial intelligence has demonstrated clinical-grade diagnostic accuracy. Published in Nature Communications, the innovative system records heart mechanical motion via radar sensing and analyses it using neural networks, enabling detection without physical contact and potentially facilitating early diagnosis before symptoms appear.
Edwards Lifesciences has obtained European regulatory approval for its SAPIEN M3 system, making it the world’s first transcatheter mitral valve replacement therapy delivered via a transfemoral approach for treating mitral regurgitation.
Phase II trial demonstrates superior outcomes compared to synthetic grafts in both civilian and military settings, with significantly lower amputation rates and infection risks.
A European research initiative has made significant progress in identifying new treatments to protect heart muscle during acute cardiac events, with potential implications for both diabetic and non-diabetic patients.
April 2024
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
College of Design and Engineering at NUS